Use of canagliflozin in preparation of antitumor drug
US11534448B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 4, 2019 |
| Grant date | Dec 27, 2022 |
| Priority date | — |
| Expiry date | Nov 4, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a use of canagliflozin in preparation of an antitumor drug, especially in preparation of a drug for treating solid tumors. It has been proven through researches that canagliflozin has a significant down-regulation effect on immune checkpoint protein PD-L1 in various tumor cells and can effectively enhance the killing effect of T cells on tumor cells in a co-incubation model of T cells and tumor cells, thereby broadening a clinical application scope of the chemical drug canagliflozin in tumor immunotherapy. The present invention provides a new medical use of canagliflozin, and also provides new approaches and potential targets for the development of small molecular drugs based on PD-L1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.